Can I read Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report on EtoBox?

Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report by Jie Li; Junwei Liu; Guqin Zhang; Weidong Hu; Xianguo Wang; Jun Liu is a Medicine article available to read on EtoBox.

What is Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report about?

Patient: Male, 54-year-old Final Diagnosis: Lung adenocarcinoma Symptoms: Cough Clinical Procedure: — Specialty: Oncology • Pulmonology ## Objective: **Unusual or unexpected effect of treatment** ## Background: Chemotherapy has been the conventional treatment method for advanced non-small-cell lung cancer (NSCLC). Nevertheless, the identification and comprehension of oncogenic driver alterations have paved the way for targeted therapies, significantly enhancing patient outcomes. The management of locally advanced NSCLC that is positive for ALK presents a challenge due to the lack of reported randomized controlled trials. The efficacy of neoadjuvant and adjuvant targeted therapy in this context remains uncertain. ## Case Report: A 54-year-old man was diagnosed with stage IIIB (pT1N3M0) upper right lung adenocarcinoma carrying the EML4-ALK fusion gene. Clinically, the patient had multiple enlarged lymph nodes in the right hilum and mediastinum, with the largest measuring approximately 28×19 mm by CT scan and we found that the L4 lymph node was invaded by metastasis. Then, the patient received 1 cycle of chemotherapy with paclitaxel in combination with nedaplatin and subsequently rece

Who reads Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report?

Author

Jie Li; Junwei Liu; Guqin Zhang; Weidong Hu; Xianguo Wang; Jun Liu

Publisher

International Scientific Information, Inc.

Published

2023

Field

Medicine (Health Sciences)